CXV GLOBAL AND PANACEA TECHNOLOGIES COMBINE TO CREATE LEADING PROVIDER OF SOLUTIONS OPTIMIZING LIFE SCIENCES OPERATIONS – Yahoo Finance
Newly Created Platform Offers Full Spectrum of Automation & Digitization Solutions to Support Entire Life Cycle of Pharmaceutical and Medical Technology Products
Water Street Healthcare Partners Commits Significant Capital to Continue Expansion; Recruits Brendan McAtamney as Chairman
News Summary
CXV Global, a strategic alliance comprised of Crest Solutions, Xyntek and VistaLink, is combining the three businesses under common ownership with Panacea Technologies. The transaction creates a leading global provider uniquely positioned to optimize life sciences operations
Market Situation: as life sciences companies develop, produce and distribute medications, emerging therapies and advanced medical technologies, finding a technology solutions provider who can address the full scope of their evolving and increasingly complex worldwide operations is challenging
This strategic transaction transforms this dynamic, offering life sciences companies a comprehensive portfolio of innovative solutions that automate and digitize their worldwide network of operations across the entire product life cycle
Water Street Healthcare Partners, a strategic health care investor, has committed significant capital to expand the new platform’s global offering and recruited Brendan McAtamney, former CEO of UDG Healthcare, as chairman
CORK, Ireland and PHILADELPHIA, Oct. 12, 2022 /PRNewswire/ — CXV Global, a strategic alliance comprised of European and U.S.-based Crest Solutions, Xyntek Incorporated and VistaLink, announced today that it is combining the three businesses under common ownership with Philadelphia-headquartered Panacea Technologies. The transaction creates a leading global provider of automation and digitization solutions uniquely positioned to optimize life sciences organizations’ worldwide operations.
The combination of CXV Global and Panacea’s innovative technologies and capabilities is unparalleled.
As companies expand and enhance their operations to develop, produce and distribute products ranging from traditional medications to emerging therapies and advanced medical technologies, finding a provider who can address the full scope of their global operational needs is challenging. By joining forces, CXV Global and Panacea Technologies transform this dynamic. Together, they offer life sciences companies a comprehensive portfolio of technologies and professional services that maximize the efficiency of their worldwide operations across their entire product life cycle.
Frank Madden, co-founder and chief executive officer of CXV Global, said:
“This strategic transaction accelerates our expansion to support our customers’ growing operational demands. Since forming CXV Global in 2020, Crest, Xyntek and VistaLink have seen firsthand the greater impact we can make serving clients together. Bringing CXV Global and Panacea Technologies together under common ownership bolsters our ability to optimize and support the full scope of our clients’ product operations, from development through distribution, wherever and whenever they need.”
Abhijit C. Jog, founder and chief executive officer of Panacea Technologies, added:
“CXV Global’s culture and commitment to serving their customers are incredibly similar to ours. We both have developed new technologies and expanded our capabilities as our customers’ needs have grown and changed. Combining our life sciences expertise and world-class solutions is a natural next step toward advancing our work to meaningfully contribute to our customers’ goals for bringing new therapies to market.“
Powerful Platform of Combined Capabilities
CXV Global and Panacea Technologies offer a powerful platform of combined technologies and professional services that optimize life sciences’ operations across product development, manufacturing, packaging and distribution. Key features include:
a comprehensive portfolio of innovative automation solutions and digitization capabilities encompassing machine vision, serialization, digitization, and resourcing for R&D and manufacturing sites
an extensive global network anchored by a strong presence in two of the world’s largest life sciences markets: Europe and the U.S.
24×7 production activity and multi-site, multi-national and multi-lingual project support spanning 10 time zones
high-touch service from a global workforce of 500+ employees possessing deep technical and engineering expertise
Strategic Healthcare Investor
CXV Global and Panacea Technologies also announced that they have partnered with strategic health care investor Water Street Healthcare Partners to build on their newly combined offering. Water Street has committed significant capital to expand the new platform’s global footprint and solutions.
Chairman Appointment
In addition, Water Street engaged its industry network to recruit Brendan McAtamney as chairman of the new platform. A highly accomplished pharmaceutical executive, Mr. McAtamney recently retired as CEO of UDG Healthcare following a distinguished career at Abbott Laboratories. He currently serves as chairman of Sharp Services and vice chairman of Inizio.
Brendan McAtamney, newly appointed chairman, stated:
“I am excited to be part of building a much-needed solution to advance the critical work of pharmaceutical and medical technology companies. The combination of CXV Global and Panacea’s innovative technologies and capabilities is unparalleled. Working with their talented leadership team, we have a tremendous opportunity to make a difference in our industry.”
Financial details of the transaction and Water Street’s investment were not disclosed.
About CXV Global
CXV Global develops and delivers proprietary solutions to automate R&D, manufacturing, packaging and distribution operations for life sciences organizations. The company began as a strategic alliance in 2020 when Crest Solutions, Xyntek Incorporated and VistaLink came together in response to customer requests for an integrated global automation solution. CXV Global operates in Ireland, Benelux, Scandinavia, the United Kingdom and the United States. To learn more, visit cxvglobal.com.
About Panacea Technologies
Panacea Technologies specializes in world-class products and services that automate manufacturing for biopharmaceutical products, including cell and gene therapies. The company was founded in 1996 when it spearheaded the automation design for the largest biotech facility in the world. Highly regarded for its engineering expertise, Panacea has received industry awards recognizing its innovation and systems integration. The company is headquartered in Philadelphia. To learn more, visit panaceatech.com.
About Water Street Healthcare Partners
Water Street Healthcare Partners is a strategic investor focused exclusively on the health care industry. The firm is one of the most active and accomplished investors in health care, having completed more than 150 investments and acquisitions to build 35+ market-leading companies contributing to improved patient care, innovation and a more efficient healthcare system. Working closely with founders and management teams, Water Street aligns its deep industry expertise and network of resources to support their growth objectives. Based in Chicago, Water Street’s team is a unique blend of highly experienced health care executives, investment professionals and functional specialists. For more information, visit waterstreet.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cxv-global-and-panacea-technologies-combine-to-create-leading-provider-of-solutions-optimizing-life-sciences-operations-301646770.html
SOURCE CXV Global and Panacea Technologies
Shares of Moderna surged more than 11% on Wednesday after the biotech company [announced](https://investors.modernatx.com/news/news-details/2022/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine/default.aspx) it would develop and sell a personalized cancer vaccine with Merck. The stock was the biggest gainer on the S 500 around midday. Shares of Merck were little changed. Merck will pay Moderna $250 m
Energy inflation remains a serious concern. Protect your portfolio.
All eyes will be on the upcoming US consumer price figures. Minutes released on Wednesday from the Fed’s last meeting suggested some officials considered reducing the pace of rate hikes.
The big question: Has the market hit a bottom yet? Well, according to Oppenheimer's Head of Technical Analysis Ari Wald, there are signs one is forming, the most notable of which is that the Russell 2000 index – the barometer for small-cap stocks – “held to the June lows in the most recent late Q3 move to the downside." Wald also notes that the signal of a market top is when the S&P 500 makes a “higher high, and small caps make a lower high," and we are currently seeing the opposite scenario pla
The headwinds have piled up for the US economy, and today’s producer price index, coming in well above the forecasts, was just the latest blow. As the PPI reminds us, inflation is stubbornly high, and compounding on last year’s elevated numbers. In addition, we’re facing a 1H GDP contraction, a nosedive in consumer confidence, shaky supplies chains, and the Federal Reserve’s rapid shift to hiking interest rates. And all of that may just be the tip of the iceberg. Billionaire investor Ray Dalio s
AMD's preliminary Q3 results contributed to a massive sell-off in the stock, but many believe this reaction was overblown.
The benchmark S&P 500, which is typically viewed as the most encompassing barometer of stock market health, delivered its worst first-half return since Richard Nixon was president. The Dow Jones Industrial Average and Nasdaq Composite haven't fared any better, with both indexes mired in a bear market. A "stock split" is a mechanism that allows a publicly traded company to alter its share price and outstanding share count without affecting its market cap or operations.
Investors often favor that industry during tough times because its earnings are less at risk — patients can't do without the products these companies sell. Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon. Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.
Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived.
It has been awful time for investors in media company Warner Bros. Discovery (NASDAQ: WBD). The potential synergies and economies of scale looked to position the combined company well to compete in the media and entertainment industry. Since the merger was structured so that AT&T would spin off its holding of WarnerMedia and then merge the company with Discovery, AT&T investors got shares of the new company without doing anything.
TSMC, the world's largest contract chipmaker, on Thursday beat targets for the third quarter and guided higher for the current period.
In this article, we shall discuss the top 12 picks in Carl Icahn’s stock portfolio. To skip our detailed analysis of Icahn’s history, his investment strategy, and hedge fund performance, go directly and see Carl Icahn Stock Portfolio: Top 5 Picks. Carl Icahn is an American financier and currently serves as the Chief Executive Officer […]
FedEx, Nike and Carnival have been highlighted in this Earnings Trends article.
U.S. stock futures edged higher Thursday ahead of inflation data out this morning.
In the latest trading session, NIO Inc. (NIO) closed at $12.88, marking a +0.39% move from the previous day.
(Bloomberg) — At first blush, Bitcoin becoming less volatile than stocks might appear like a positive development. But crypto traders are warning that in a low-volume environment, that might not be a great thing. Most Read from BloombergIntel Is Planning Thousands of Job Cuts in Face of PC SlumpHere’s How Weird Things Are Getting in the Housing MarketPutin Says All Infrastructure at Risk After Nord Stream HitAlex Jones Must Pay $965 Million for His Sandy Hook LiesThe coin’s 30-day realized vola
(Bloomberg) — JPMorgan Chase & Co.’s boss Jamie Dimon says the US stock market could suffer another “easy 20%” drop, which would push the benchmark index below 3,000 — a level it hasn’t seen since the depths of the coronavirus pandemic. So what would another slide of that magnitude actually look like and which stocks would get hit hardest? For one thing, it would be painful for investors, with technology and so-called growth shares likely taking the brunt of the suffering, with their elevated
"The travel recovery continues as consumer spend shifts to experiences and demand improves in corporate and international," said CEO Ed Bastian.
In contrast to many other biotechs, CTI stock has done fairly well this year — in fact, it has nearly doubled since the beginning of this year. This seems to be the dynamic behind CTI's Wednesday fall.
This is what's happening with Medical Properties Trust (NYSE: MPW) right now. Medical Properties owns more than 440 facilities in its health-focused portfolio, spanning 10 countries (the majority, 61%, are in the U.S.). Despite focusing on a healthcare industry that should provide long-term stability, that hasn't helped this real estate investment trust (REIT) avoid a disastrous performance in 2022.